News Denmark's Genmab prepares for $500m US IPO Antibody-based drugs firm Genmab, noted for developing the blood cancer drug Darzalex with Johnson & Johnson’s Janssen unit, is preparing for a $500 million US IPO.
News ‘Trojan horse’ cancer drug shows promise in multiple tumour ... A new type of cancer drug that acts as a ‘Trojan horse’ to get inside tumour cells has shown promise in patients with six different cancer types.
News J&J rumoured to be sizing up $12bn Genmab acquisition Speculation mounts that J&J will bid for R&D partner
News Novartis' Arzerra gains CLL approval Development partner Genmab says drug approved in relapsed disease.
News Remepy's hybrid Parkinson's therapy poised for phase 3 Remepy's Hybridopa therapy for Parkinson's, which combines an app with levodopa therapy, has shown efficacy in a phase 2 pilot study.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
